Commissioner of human services required to select a state pharmacy benefit manager through procurement, commissioner required to enter into a master contract with the state pharmacy benefit manager, program authority and eligibility requirements specified, and report required.
HF2242 would create a new state-run pharmacy benefit manager structure for prescription drug coverage in Minnesota’s managed care system for Medical Assistance and MinnesotaCare enrollees. The bill requires the commissioner of human services to use a competitive procurement process to select a single pharmacy benefit manager, enter into a master contract with that entity, and make that manager the exclusive PBM for managed care plans. It also bars the selected PBM from forcing enrollees to use a specialty pharmacy owned or affiliated with the PBM.
The bill gives the commissioner broad oversight authority over drug coverage, including approval of utilization management rules, reimbursement rates, and other drug-related payment arrangements. It also authorizes the commissioner, in consultation with the Formulary Committee, to develop or adopt a preferred drug list, manage a formulary, and even negotiate directly with manufacturers, wholesalers, or group purchasing organizations if needed. The bill is designed to increase transparency, lower drug costs, and improve administration of pharmacy benefits for managed care enrollees.
The bill would amend Minnesota Statutes section 256B.69 and add a new section in chapter 256B governing prescription drugs under the managed care delivery system. It would shift pharmacy benefit management for managed care enrollees to a single state-selected PBM, require extensive disclosure of rebates, fees, ownership ties, and manufacturer arrangements, and impose quarterly reporting obligations on the PBM and managed care plans. It also allows the commissioner to review and amend pharmacy contracts for compliance and requires federal approval before implementation, with an effective date of January 1, 2027, or later if federal approval is delayed.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears policy-driven and reform-oriented rather than overtly partisan in the available record. The bill’s stated goals are lower prescription drug costs, greater transparency, and stronger state oversight of pharmacy benefit management. Because no committee discussion or vote history is included, there is no documented public support or opposition in the provided context beyond the bill’s structural emphasis on cost control and accountability.
The main points of potential contention are the bill’s centralization of pharmacy benefit management in a single state-selected entity and the commissioner’s expanded authority over drug coverage, pricing, and formulary decisions. Pharmacies and PBMs may object to the disclosure requirements, contract review authority, and limits on affiliated specialty pharmacy use, while managed care plans may resist losing control over pharmacy benefit administration. Another likely issue is whether the state can implement the model under federal Medicaid and MinnesotaCare rules, since the bill is contingent on federal approval and may require changes to existing managed care contracts.